{"name":"GWT-TUD GmbH","slug":"gwt-tud-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Acnatac® Gel left face","genericName":"Acnatac® Gel left face","slug":"acnatac-gel-left-face","indication":"Acne vulgaris","status":"marketed"},{"name":"Acnatac® Gel right face","genericName":"Acnatac® Gel right face","slug":"acnatac-gel-right-face","indication":"Acne vulgaris","status":"marketed"},{"name":"Epiduo® Gel right face","genericName":"Epiduo® Gel right face","slug":"epiduo-gel-right-face","indication":"Acne vulgaris","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Epiduo® Gel left face","genericName":"Epiduo® Gel left face","slug":"epiduo-gel-left-face","indication":"Other","status":"marketed"},{"name":"Secukinumab 300 mg","genericName":"Secukinumab 300 mg","slug":"secukinumab-300-mg","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"e.-coli-nissle","genericName":"e.-coli-nissle","slug":"e-coli-nissle","indication":"Ulcerative colitis","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"nicotine acid","genericName":"nicotine acid","slug":"nicotine-acid","indication":"Hypercholesterolemia","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"pazopanib or guideline conform chemotherapy","genericName":"pazopanib or guideline conform chemotherapy","slug":"pazopanib-or-guideline-conform-chemotherapy","indication":"Advanced renal cell carcinoma","status":"marketed"}]}],"pipeline":[{"name":"Acnatac® Gel left face","genericName":"Acnatac® Gel left face","slug":"acnatac-gel-left-face","phase":"marketed","mechanism":"Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and inflammation on the skin.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Acnatac® Gel right face","genericName":"Acnatac® Gel right face","slug":"acnatac-gel-right-face","phase":"marketed","mechanism":"Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial and keratolytic agent) to reduce acne-causing bacteria and promote skin cell turnover.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Epiduo® Gel left face","genericName":"Epiduo® Gel left face","slug":"epiduo-gel-left-face","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Epiduo® Gel right face","genericName":"Epiduo® Gel right face","slug":"epiduo-gel-right-face","phase":"marketed","mechanism":"Epiduo combines adapalene (a retinoid) and benzoyl peroxide to reduce acne by normalizing skin cell turnover and killing acne-causing bacteria.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Secukinumab 300 mg","genericName":"Secukinumab 300 mg","slug":"secukinumab-300-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"e.-coli-nissle","genericName":"e.-coli-nissle","slug":"e-coli-nissle","phase":"phase_3","mechanism":"E. coli Nissle is a probiotic bacterium that modulates the gut microbiome to exert its therapeutic effects.","indications":["Ulcerative colitis","Irritable bowel syndrome"],"catalyst":""},{"name":"nicotine acid","genericName":"nicotine acid","slug":"nicotine-acid","phase":"phase_3","mechanism":"Nicotine acid, also known as niacin, primarily functions by reducing the production of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol in the liver.","indications":["Hypercholesterolemia","Mixed dyslipidemia"],"catalyst":""},{"name":"pazopanib or guideline conform chemotherapy","genericName":"pazopanib or guideline conform chemotherapy","slug":"pazopanib-or-guideline-conform-chemotherapy","phase":"marketed","mechanism":"Pazopanib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor cell proliferation by inhibiting VEGFR, PDGFR, and c-Kit signaling.","indications":["Advanced renal cell carcinoma","Advanced soft tissue sarcoma","Ovarian cancer (in combination with chemotherapy)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":8,"phaseCounts":{"marketed":6,"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}